We examined the contribution of large-conductance, Ca 2+ -sensitive K + (MaxiK) channel to β2-adrenoceptor-activated relaxation to isoprenaline in guinea-pig tracheal smooth muscle focusing on the role for cAMP in the coupling between β2-adrenoceptor and MaxiK channel. Isoprenaline-elicited relaxation was confirmed to be mediated through β2-type of adrenoceptor since the response was antagonized in a competitive fashion by a β2-selective adrenoceptor antagonist butoxamine with a pA2 value of 6.56. Isoprenaline-induced relaxation was significantly potentiated by a selective inhibitor of cyclic AMP-specific phosphodiesterase, Ro-20-1724 (0.1-1 µM). cAMP-dependent mediation of MaxiK channel in the relaxant response to isoprenaline was evidenced since the potentiated response to isoprenaline by the presence of Ro-20-1724 (1 µM) was inhibited by the channel selective blocker, iberiotoxin (IbTx, 100 nM). This concept was supported by the finding that the relaxation to a membrane permeable cAMP analogue, 8-bromo-cAMP (1 mM), was susceptible to the inhibition by IbTx. On the other hand, isoprenaline-induced relaxation was not practically diminished by an adenylyl cyclase inhibitor SQ 22,536 (100 µM). However, isoprenaline-induced relaxation in the presence of SQ 22,536 was suppressed by IbTx. Characteristics of isoprenaline-induced relaxant response, i.e., impervious to SQ 22,536 but susceptible to IbTx, were practically mimicked by cholera toxin (CTX, 5 µg/ml), an activator of adenylyl cyclase coupled-heterotrimeric guanine nucleotide-binding regulatory protein Gs. These findings indicate that in guinea-pig tracheal smooth muscle: 1) MaxiK channel substantially mediates β2-adrenoceptor-activated relaxation; 2) both cAMP-dependent andindependent mechanisms underlie the functional coupling between β2-adrenoceptor and MaxiK channel to induce muscle relaxation; and 3) direct regulation of MaxiK channel by Gs operates in cAMP-independent coupling between β2-adrenoceptor and this ion channel.
Introduction
Airway smooth muscle relaxes in response to the stimulation of β-adrenoceptors. β-Adrenoceptors are currently classified into three subtypes (β1, β2 and β3) (Johnson, 1998; Nagatomo and Koike, 2000) , and β2-subtype is the primary β-adrenoceptor that contributes to the control of airway smooth muscle tone (Lands et al., 1967; Torphy, 1994; Johnson, 1998; Nagatomo and Koike, 2000) . This concept can be supported pharmacologically based on the following evidence that: 1) relaxation to isoprenaline is competitively antagonized by β2-adrenoceptor antagonists ; 2) selective β2-adrenoceptor agonists produce a strong muscle relaxation (Huang et al., 1993; Jones et al., 1993) ; and 3) the potencies of three catecholamines to produce muscle relaxation are ranked as isoprenaline > adrenaline > noradrenaline vs. isoprenaline > adrenaline = noradrenaline for β1-adrenoceptor (Nagatomo and Koike, 2000) . Abundant distribution of β2-receptor in airway smooth muscle also supports the relevant role for this subtype of β-adrenoceptor in the mechanical responses of this muscle (Johnson, 1998; Nagatomo and Koike, 2000) .
The mechanisms by which β2-adrenoceptor-activated relaxation of airway smooth muscle are, however, not fully revealed. So far, cAMP has been believed to be a key molecule that mediates relaxant response of airway smooth muscle to the stimulation of β2-adrenoceptor (Torphy, 1994; Johnson, 1998) . The basis for this deeply engrained cAMP dogma is that isoprenaline and β2-adrenoceptor agonists elevates cAMP content through activating adenylyl cyclase that is coupled to a heterotrimeric guanine nucleotide-binding protein, Gs (Nakagawa et al., 1986; Jones et al., 1990; Ellis et al., 1995; McGrogan et al., 1995; Hoiting et al., 1996) . Furthermore, the capability of airway smooth muscle to relax in response to adenylyl cyclase activators (Tsukawaki et al., 1987; Jones et al., 1990; Devillier et al., 2001) , phosphodiesterase inhibitors (Tsukawaki et al., 1987; Jones et al., 1990; Devillier et al., 2001 ) and membranepermeable cyclic AMP analogues (Watanabe et al., 1976; Jones et al., 1990 ) also supports the primary role for cAMP in β2-adrenoceptor-activated airway smooth muscle relaxation. cAMP is considered to catalyze the activation of protein kinase A (PKA), which in turn phosphorylates key regulatory proteins associated with the control of airway smooth muscle tone (Johnson, 1998) . In contrast to this cAMP-dependent mechanism(s), mechanism(s) independent of cAMP might also be significant in the relaxation of airway smooth muscle mediated through β2-adrenoceptor (Torphy, 1994; Johnson, 1998) . This challenging idea can be deducted from the findings that inhibition of the activity of adenylyl cyclase does not affect β (β3)-adrenoceptormediated relaxation of gastrointestinal smooth muscles (Horinouchi et al., 2002) , and prostacyclin receptor (IP receptor)-mediated relaxation of vascular smooth muscle (Turcato et al., 1999; Yamaki et al., 2001) . A question on the exclusive role for cAMP-dependent mechanism(s) is also raised in β2-adrenoceptor-mediated inhibition of histamine-stimulated phosphoinositide turnover in bovine tracheal smooth muscle (Chilvers et al., 1997) . These findings indicate the high degree of necessity for re-evaluation of cAMP role in β2-adrenoceptormediated relaxation of airway smooth muscle.
On the other hand, recent pharmacological evidence shows the relevant role for largeconductance, Ca 2+ -sensitive K + (MaxiK) channel (Nelson et al., 1995; Toro et al., 1998) in the airway smooth muscle relaxation to the stimulation of β2-adrenoceptor (Jones et al., 1990; Huang et al., 1993; Jones et al., 1993; Satake et al., 1998) . Activation of this ion channel leads to membrane hyperpolarization, suppression of Ca 2+ entry through L-type Ca 2+ channel and thus smooth muscle relaxation (Nelson et al., 1995; Toro et al., 1998) . β (β2)-Adrenoceptor-mediated, MaxiK channel activation mechanisms include channel phosphorylation due to PKA (cAMPdependent mechanism) (Kume et al., 1989) . In addition, activity of this ion channel is also enhanced through direct regulation of the channel by Gs (cAMP-independent mechanism) (Kume et al., 1994) . However, the role for cAMP in the coupling between β2-adrenoceptor and MaxiK channel to elicit airway smooth muscle relaxation still remains unknown; is MaxiK channel-mediated relaxant response elicited through cAMP-dependent mechanism(s) or cAMPindependent mechanism(s)? Or, do both mechanisms underlie the MaxiK channel-mediated relaxation? The present study was thus carried out to answer this question in isoprenalineinduced relaxation of guinea-pig tracheal smooth muscle.
Materials and Methods
Male or female Hartley guinea-pigs weighing 300-600 g (Saitama Experimental Animals Co., Ltd, Saitama, Japan) were used in the present study. Guinea-pigs were housed in the rooms in which temperature (20-22°C) and relative air humidity (50 ± 5%) were strictly regulated. Food and water were available ad libitum to all animals. This study was conducted in accordance with the Guideline for the Care and Use of Laboratory Animals adopted by the Committee on the Care and Use of Laboratory Animals of Toho University School of Pharmaceutical Sciences (accredited by The Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Japan).
Preparation of tracheal tissue
Guinea-pigs were killed by cervical dislocation and exsanguinated from the common carotid or external iliac artery. Tracheal tissues were carefully isolated and immersed in Ringer-Locke solution (mM: NaCl, 154.0; KCl, 5.6; CaCl2, 2.2; MgCl2, 2.1; NaHCO3, 5.9; and glucose, 2.8) bubbled with a mixture of 95% O2 and 5% CO2. The tracheal tissues were cleaned of unnecessary adipose and connective tissues under a dissecting microscope very cautiously so that smooth muscles were not damaged. Subsequently, tracheal cartilage containing smooth muscles were cut into 2-mm long pieces. In this series of experiments, tracheal epithelium was removed by rubbing gently the intimal surface of tracheal tissue.
Measurement of tension changes
Preparations were suspended using stainless steel hooks (outer diameter, 200 µm) in a 5-ml organ bath (UC-5; UFER Medical Instrument, Kyoto, Japan) containing Ringer-Locke solution which was maintained at 36 ± 1°C and bubbled with the O2-CO2 mixture. Tension changes of the tracheal preparation were isometrically recorded with a force-displacement transducer (T7-8-240; Orientec, Tokyo, Japan) connected to an amplifier (high-gain DC amplifier: model, AD 632J; Nihon Kohden, Tokyo, Japan).
Assessment of relaxants on the muscle tone
Effects of muscle relaxants were examined in general as follows. In this tracheal tissue, when the preparation was preloaded with an initial tension increase (2.0 × g), a spontaneous tension development was generated after its application. During the tension development due to stretch, the bath solution was renewed every 20 min for 60 min. This spontaneous tension development lasted for several hours without an appreciable decline. Sixty min after applying the initial tension increase, muscle was contracted with histamine (10 µM) for 15 min, which was subsequently washed out. After this procedure, tracheal preparation was incubated for another 60 min with 20 min-interval renewal of bath solution, and was contracted again with 10 µM histamine. When the active tension obtained with histamine and initial muscle stretch reached a steady-state level 20-30 min after the application of histamine, relaxants (isoprenaline, adrenaline, noradrenaline, and cholera toxin (CTX)) were applied cumulatively (for catecholamines) or in a single shot (for CTX) to the bath medium until their maximum relaxant response was obtained. At the end of each experiment, papaverine (100 µM) was applied to the bath medium to obtain the substantially maximum relaxant level.
Assessment of the effects of butoxamine on the response to isoprenaline
When the effects of butoxamine, a β2-selective adrenoceptor antagonist, on the relaxant response to isoprenaline were examined, this antagonist (1-10 µM) was applied to the bath medium 5 min before cumulative administration of isoprenaline.
Assessment of the effects of Ro-20-1724 on the response to isoprenaline
When the effects of Ro-20-1724 (4-(butoxy-4-methoxybenzyl)-2-imidazolidinone), a selective inhibitor of cAMP-specific phosphodiesterase (soluble cGMP-insensitive type IV PDE) (Katano et al., 1990) , on the response to isoprenaline were examined, this inhibitor (10 nM-1 µM) was applied to the bath medium 20 min before administration of histamine (10 µM) (i.e., 50 min before cumulative administration of isoprenaline).
Assessment of the effects of SQ 22,536 on the responses to isoprenaline and CTX
When the effects of SQ 22,536 (9-(tetrahydro-2-furanyl)-9H-purin-6-amine), an inhibitor of adenylyl cyclase (Turcato and Clapp, 1999) , on the responses to isoprenaline and CTX were examined, this inhibitor (100 µM) was applied to the bath medium simultaneously with histamine (10 µM). Twenty min (for isoprenaline) or 30 min (for CTX) after their application, relaxants were applied cumulatively (for isoprenaline) or in a single concentration (for CTX, 5 µg/ml).
Assessment of the effects of iberiotoxin (IbTx) on the responses to isoprenaline, 8-bromo-cyclic AMP (8-Br-cAMP) and CTX
Significant role for MaxiK channel in the relaxant responses to isoprenaline, 8-Br-cAMP and CTX was determined with its selective channel blocker, IbTx (Galvez et al., 1990; Wallner et al., 1995) . IbTx (100 nM) was added to the bath medium simultaneously with histamine (10 µM). However, in the presence of IbTx, spontaneous, irregular tension changes (contractions) were generated during the relaxant response to each stimulant (see Fig. 1A ). Due to this atypical relaxant characteristic, it was practically impossible to determine the maximum relaxant levels attained with each relaxant in the presence of IbTx. Therefore, in this study, to evaluate the (100 nM). When the muscle contraction induced by histamine (His, 10 µM), which was generated on spontaneous contraction, reached a steady-state level, isoprenaline (ISO) was applied to the bath medium in a single concentration. Tension changes of tracheal smooth muscle were observed for 60 min, and papaverine (PPV, 100 µM) was administered to obtain the maximum relaxant level. In the presence of IbTx, spontaneous contractions were generated during the relaxant response to isoprenaline. Tension changes during the relaxation were completely voluntary, and were irregularly characteristic in their generation timing and amplitude etc. B: A schematic diagram showing the method to evaluate the effects of IbTx on the relaxant response to isoprenaline. The details were given in Materials and methods section. Relaxant activity (%) for isoprenaline was defined as the ratio between S1 and S0 ((S1/S0) × 100). The relaxant activities for 8-BrcAMP ( Fig. 4C) and CTX ( Fig. 6B ) were calculated in an almost similar way.
effects of IbTx on the relaxant responses, the following procedure was adopted (Fig. 1B) . First, the circumscribed area on the recording chart under the relaxant response to a single concentration of each stimulant (isoprenaline, 8-Br-cAMP and CTX) (S1) was measured with a planimeter (Placom KP-21C; Koizumi, Tokyo, Japan). Observation periods for each relaxant response were set as: 60 min for isoprenaline and 8-Br-cAMP, and 360 min (6 hr) for CTX. Secondly, the area surrounded by the maximum relaxation (the differences between the tension level before relaxant administration and the maximally relaxed tension level obtained with 100 µM papaverine) multiplied by the observation time (60 min or 360 min) (S0) was obtained.
Relaxant activity (%) for each stimulant was defined as the ratio between S1 and S0 ((S1/S0) × 100). In this series of experiments, histamine (10 µM) was applied 90 min (for isoprenaline and 8-Br-cAMP) or 30 min (for CTX) before administration of each relaxant. Ro-20-1724 (1 µM) and SQ 22,536 (100 µM) were applied together with histamine (10 µM).
Drugs
Drugs used in the present study were as follows: (-)-isoprenaline hydrochloride, histamine dihydrochloride, (-)-adrenaline (+)-bitartrate, (-)-noradrenaline (+)-bitartrate, papaverine hydrochloride (Sigma-Aldrich Co., St. Louis, Mo., USA); 9-(tetrahydro-2-furanyl)-9H-purin-6-amine (SQ 22,536) (Sigma-RBI, St. Louis, Mo., USA); iberiotoxin (IbTx) (Peptide Institute, Minoh-City, Osaka, Japan); 4-(butoxy-4-methoxybenzyl)-2-imidazolidinone (Ro-20-1724) (Biomol Research Laboratories, Plymouth Meeting, Pa., USA); 8-bromo-cyclic AMP (8-Br-cAMP) (BIOLOG Life Science Institute, Bremen, Germany). All other chemicals used were of analytical grade. Ro-20-1724 was dissolved in ethanol to make a stock solution of 50 mM and diluted with distilled water. For other drugs, distilled water was used to their dissolution and dilution. All drugs are expressed in molar concentrations in the bathing solution.
Data analysis and statistics
To construct concentration-response relationships for the relaxations induced by catecholamines including isoprenaline, percentage of the relaxant response was calculated considering the tension level before application of catecholamines (spontaneous tone plus histamine-elicited tension) as 0% and the maximum relaxation obtained after application of 100 µM papaverine as 100%. Data were plotted as a function of catecholamines concentration and fitted to the equation: E = Emax × A n H / (EC50 n H + A n H ) where E is the percentage relaxation at a given catecholamine concentration, Emax is the maximum relaxation, A is the concentration of catecholamines, nH is the slope function and EC50 is the effective catecholamine concentration that produce a 50% response. The curve fitting was carried out using GraphPad Prism™ (Version 4.00) (GraphPad Software, Inc., San Diego, Calif., USA). The EC50 values were converted to logarithmic values (pD2, -logEC50) for statistical analysis. The competitive antagonistic potency of butoxamine was expressed as pA2 value, which was calculated according to the method originally reported by Arunlakshana and Schild (1959) .
Data are presented as means ± S.E.M. or mean values with 95% confidence intervals and n refers to the number of experiments. The significance of the difference between mean values was evaluated with GraphPad Prism™ by unpaired t-test, unpaired t-test with Welch's correction if necessary, and one-way analysis of variance (one-way ANOVA) followed by Dunnett's multiple comparison test. A P value less than 0.05 was considered statistically significant.
Results

β2-Type of adrenoceptor mediates relaxation of guinea-pig tracheal smooth muscle in response to isoprenaline
Isoprenaline relaxed guinea-pig tracheal smooth muscle in a concentration-dependent fashion ( Fig. 2A , open circles) with a pD2 value of 8.05 ± 0.14 (n=3). Concentration-response curves for isoprenaline were shifted rightward in a parallel fashion by butoxamine (a β2-selective adrenoceptor antagonist) ( Fig. 2A, filled symbols) . Schild plot analysis gave a straight line with a slope of 0.97 (95% confidence intervals: 0.84-1.11) and pA2 value of 6.56 (95% confidence intervals: 6.43-6.74) (n=9 for each) ( Fig. 2A, inset) . Relaxant response to isoprenaline was also antagonized competitively by other β-adrenoceptor antagonists (propranolol, atenolol and bupranolol) with their corresponding pA2 values against β2-adrenoceptor (data not shown). Fig. 2 . Evidence of the primary role for β2-subtype of adrenoceptor that mediates the relaxant response of guinea-pig tracheal smooth muscle. A: Concentration-response relationships for isoprenaline-elicited relaxation in the absence and presence of varied concentrations of (±)-butoxamine. Muscle relaxation is calculated with respect to the tension level before administration of isoprenaline (0% relaxation) and the maximally relaxed tension level attained with papaverine (100 µM) (100% relaxation). Data are means ± S.E.M. of three experiments for each. The maximum relaxations to isoprenaline are: control (open circles), 98.6 ± 0.2%; 1 µM butoxamine (filled circles), 96.9 ± 1.7%; 3 µM butoxamine (filled triangles), 98.0 ± 0.7%; 10 µM butoxamine (filled squares), 97.9 ± 0.7%. Inset:
The Schild plot analysis for competitive antagonism between isoprenaline vs. butoxamine. B: Concentration-response relationships for the relaxant responses to three catecholamines (isoprenaline, ISO; adrenaline, Ad; noradrenaline, NA). Data are means ± S.E.M. of 15-21 experiments. The maximum relaxations are: isoprenaline, 98.6 ± 0.2% (n=21); adrenaline, 97.4 ± 0.5% (n=18); noradrenaline, 97.4 ± 0.4% (n=15).
Fig . 2B shows the comparison for the potencies of three catecholamines (isoprenaline, adrenaline and noradrenaline) to produce a tracheal relaxation. Based on the pD2 values, the relaxant potencies for these catecholamines were ranked as: isoprenaline (pD2 = 8.23 ± 0.03, n=21) > adrenaline (pD2 = 7.08 ± 0.06, n=18) > noradrenaline (pD2 = 5.83 ± 0.07, n=15). Fig. 3 shows the effects of a MaxiK channel selective blocker, iberiotoxin (IbTx), on the relaxant response of tracheal smooth muscle to isoprenaline. IbTx (100 nM) significantly inhibited the response to isoprenaline in a wide range of this catecholamine concentrations (3 nM-100 nM). However, at higher concentrations (in this case, at 1 µM), the relaxation to isoprenaline was not affected by IbTx.
MaxiK channel substantially contributes to isoprenaline-induced tracheal relaxation
cAMP-dependent mechanism is significant in MaxiK channel-mediated relaxation to isoprenaline
Fig . 4A shows the effects of Ro-20-1724 on the tracheal relaxation induced by isoprenaline. Isoprenaline-induced relaxation was potentiated by the presence of Ro-20-1724, which was evident from the leftward shift of the concentration-response curves for isoprenaline with increase in the concentrations of Ro-20-1724 (100 nM-1 µM). This was reflected by the significant increment of pD2 value for isoprenaline: control, 8.41 ± 0.05; 10 nM Ro-20-1724, 8.46 ± 0.04; 100 nM Ro-20-1724, 8 .70 ± 0.06 (P<0.01 vs. control, Dunnett's multiple comparison test); 1 µM Ro-20-1724, 9.08 ± 0.07 (P<0.01 vs. control, Dunnett's multiple comparison test) (n=5 for each). Fig. 4B shows the effects of IbTx on the relaxant response to isoprenaline potentiated by Ro-20-1724. The potentiated response to isoprenaline by Ro-20-1724 (1 µM) was practically inhibited by IbTx (100 nM) in a concentration ranges from 0.3 nM-10 nM. IbTx (100 nM) also significantly attenuated the relaxation induced by a membrane permeable cAMP analogue, 8-bromo-cAMP (8-Br-cAMP) (Fig. 4C) .
cAMP-independent mechanism is also significant in MaxiK channel-mediated relaxation to isoprenaline Fig. 5A shows the effects of SQ 22,536 on the tracheal relaxation induced by isoprenaline. Isoprenaline-induced relaxation was not practically inhibited by SQ 22,536 (100 µM), which was evident from the insignificant changes in the maximum response (control, 98.3 ± 0.70% vs. SQ 22,536, 97.0 ± 1.4%, n=4, P>0.05). pD2 Values for isoprenaline was slightly increased by SQ 22, 536 (control, 8.20 ± 0.05 vs. SQ 22, 536, 8.38 ± 0.03, n=4, P<0.05) . Fig. 5B shows the effects of IbTx on the relaxant response to isoprenaline in the presence of SQ 22,536. The response to isoprenaline in the presence of SQ 22,536 (100 µM) was significantly inhibited by IbTx (100 nM) at concentrations at or lower than 10 nM. However, at higher concentrations (100 nM-1 µM), IbTx effects were insignificant.
Evidence for the significant role for Gs in MaxiK channel-mediated, cAMP-independent relaxant response
Fig . 6A shows the effects of SQ 22,536 on the relaxation induced by cholera toxin (CTX). CTX (5 µg/ml)-induced relaxant response was not affected by SQ 22,536 (100 µM) (filled circles vs. filled triangles). However, IbTx (100 nM) significantly inhibited the CTX-induced relaxation elicited in the presence of SQ 22,536 (Fig. 6B) .
Discussion
The present pharmaco-mechanical study provides evidence for a functional consolidation of β2-adrenoceptor with MaxiK channel to trigger airway smooth muscle relaxation. The present study also shows for the first time that MaxiK channel is coupled with β2-adrenoceptor through cAMP-dependent and -independent mechanisms, both of which are able to trigger a substantial relaxation in guinea-pig tracheal smooth muscle.
Competitive antagonism between isoprenaline and butoxamine (a β2-selective adrenoceptor antagonist) supports a crucial role for β2-subtype of adrenoceptor that mediates the relaxant response of tracheal smooth muscle. This idea is also reinforced from the competitive inhibition of isoprenaline-induced relaxation by other β-adrenoceptor antagonists (propranolol, atenolol and bupranolol) with their corresponding pA2 values against β2-adrenoceptor . Furthermore, the rank order of pD2 values for three catecholamines (isoprenaline > adrenaline > noradrenaline) also supports the principal role for β2-subtype which mediates the relaxant response of guinea-pig tracheal smooth muscle.
MaxiK channel is the large-conductance type of Ca 2+ -sensitive K + channel and is expressed in a high density in smooth muscles including tracheal smooth muscle (Toro et al., 1998) . One of the physiological significances for this type of K + channel in smooth muscle is to mediate relaxant responses to biological active substances (Nelson and Quayle, 1995; Toro et al., 1998) .
Airway smooth muscle relaxation to the stimulation of β (β2)-adrenoceptor could be also mediated through MaxiK channel activation (Huang et al., 1993; Jones et al., 1993; Jones et al., 1990; Satake et al., 1998) . Diminishment by IbTx of isoprenaline-induced relaxation shown in the present study indicates a role for this ion channel in the response, and supports the previous finding (Jones et al., 1990; Huang et al., 1993; Jones et al., 1993; Satake et al., 1998) . However, our present findings highlighted a role for cAMP to link β2-adrenoceptor with MaxiK channel in eliciting relaxation of tracheal smooth muscle. First, we showed that MaxiK channel activation involves cAMP-dependent mechanism(s) in isoprenaline-induced relaxation. This is evidenced by the findings that IbTx significantly suppressed isoprenaline-induced relaxation potentiated by Ro-20-1724 (a selective inhibitor of cAMP-specific phosphodiesterase) and 8-Br-cAMP-induced relaxation. One of the molecular mechanisms by which elevation of cAMP enhances MaxiK channel activity is the phosphorylation of this channel by PKA (Kume et al., 1989; Scornik et al., 1993; Nara et al., 1998) . However, it is practically impossible to demonstrate in mechanical studies that this mechanism is substantial in isoprenaline-induced relaxation since PKA-specific inhibitors useful at the tissue level are not currently available, and this issue should await a future deliberation. cAMP-dependent activation of MaxiK channel associated with tracheal relaxation might include the enhancement of Ca 2+ spark frequency (Porter et al., 1998) . Secondly, we showed that MaxiK channel activation also involves cAMP-independent mechanism(s) in isoprenaline-induced relaxation. This concept is endorsed by the findings that IbTx significantly suppressed isoprenaline-induced relaxation in the presence of SQ 22,536 (an adenylyl cyclase inhibitor). SQ 22,536 is an inhibitor of adenylyl cyclase (Turcato and Clapp, 1999) , and has been shown to suppress the elevation of cAMP following stimulation of Gscoupled receptors including IP receptor (Turcato and Clapp, 1999; Yamaki et al., 2001 ) and β3-type of adrenoceptor (Horinouchi and Koike, 2002) . SQ 22,536 (100 µM) is also able to suppress the elevation of cAMP when stimulated with isoprenaline (data not shown) and CTX in this smooth muscle. Therefore, the isoprenaline-induced relaxant component generated in the presence of SQ 22,536 is supposed to be independent of cAMP.
Thirdly, we showed that cAMP-independent activation of MaxiK channel involves Gstriggered mechanism(s), such as direct channel regulation by Gs (Scornik et al., 1993; Kume et al., 1994) . This view is deduced by the finding that IbTx diminished CTX-induced relaxation in the presence of SQ 22,536; since pharmacological characteristics of isoprenaline-induced relaxation (invulnerability to SQ 22,536 and restrainability to IbTx) were practically mimicked by CTX, this implies that Gs-triggered mechanism(s) partly underlies MaxiK channel-mediated, cAMP-independent tracheal relaxation to the stimulation of β2-adrenoceptor. Possible involvement of direct regulation of MaxiK channel by Gs in cAMP-independent relaxation is also significant in IP agonist-elicited blood vessel relaxation (Yamaki et al., 2001 ). β2-Adrenoceptormediated signalling systems also involve pertussis toxin-sensitive G protein (Gi)-mediated mechanisms (Johnson, 1998) . However, since β2-adrenoceptor requires the receptor phosphorylation by PKA following the elevation of cAMP for this system being activated (Daaka et al., 1997) , involvement of Gi in cAMP-independent activation of MaxiK could be ruled out.
At present, it is practically difficult to determine the degrees of contribution of cAMPdependent and -independent mechanisms to the total β2-adrenoceptor-mediated relaxant response. Furthermore, physiological significance of each mechanism should also await a future elucidation. However, in both mechanisms, MaxiK channel roles are significant. This ion channel seems to translate β2-adrenoceptor activation signal into airway smooth muscle relaxant response possibly through smooth muscle cell membrane hyperpolarization, and plays a determinant role in the tuning of this muscle tone behaving as an apparently functional unit together with β2-adrenoceptor.
